山豆根多糖STGP-1及其制备方法和用于治疗肺鳞癌的制药用途
By preparing the Sophora tonkinensis polysaccharide STGP-1 with a well-defined structure and combining it with an anti-PD-1 monoclonal antibody, the problems of unclear structure and toxicity were solved, achieving a highly effective and safe treatment for squamous cell carcinoma of the lung.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGXI MEDICAL UNIVERSITY
- Filing Date
- 2026-05-11
- Publication Date
- 2026-07-17
AI Technical Summary
In the existing technology, the structural characterization of Sophora tonkinensis polysaccharide is unclear, the sensitization mechanism is not well understood, and there is a lack of targeted combination therapy strategies for squamous cell carcinoma of the lung. Furthermore, traditional alkaloids and flavonoids have hepatotoxicity and neurotoxicity, which limits their clinical application.
A method for preparing STGP-1, a polysaccharide from Sophora tonkinensis with a well-defined structure, is provided. High-purity STGP-1 is obtained through specific gradient elution and gel purification, which can be used in combination with anti-PD-1 monoclonal antibodies to prepare drugs against lung squamous cell carcinoma.
STGP-1 showed no significant liver, kidney, or cardiotoxicity at the same efficacy level, significantly improving clinical safety. Furthermore, its combination with anti-PD-1 monoclonal antibodies significantly enhanced anti-tumor immune effects, providing experimental evidence for novel immune enhancers and adjuvant therapy for squamous cell carcinoma of the lung.
Smart Images
Figure CN122145664B_ABST